Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Other Operating Expenses (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Other Operating Expenses for 15 consecutive years, with $2.9 million as the latest value for Q1 2026.

  • For Q1 2026, Other Operating Expenses rose 19.98% year-over-year to $2.9 million; the TTM value through Mar 2026 reached $13.5 million, up 25.18%, while the annual FY2025 figure was $13.0 million, N/A changed from the prior year.
  • Other Operating Expenses hit $2.9 million in Q1 2026 for Corcept Therapeutics, up from $2.5 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $4.6 million in Q3 2025 and bottomed at $1.2 million in Q1 2022.
  • Average Other Operating Expenses over 5 years is $2.3 million, with a median of $2.4 million recorded in 2025.
  • Year-over-year, Other Operating Expenses surged 82.9% in 2024 and then fell 13.9% in 2025.
  • Corcept Therapeutics' Other Operating Expenses stood at $1.5 million in 2022, then increased by 26.82% to $1.9 million in 2023, then soared by 57.49% to $3.0 million in 2024, then dropped by 13.9% to $2.5 million in 2025, then rose by 13.28% to $2.9 million in 2026.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $2.9 million, $2.5 million, and $4.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.